NCI-CCC Breast Tumor Board Question
Questions discussed in this category
Patient underwent an axillary dissection with ITCs in 1/23 nodes.
Would clinical stage or nodal status affect your decision?
As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays...
For a patient with high risk disease and a severe enough reaction that additional taxane-based therapy is contraindicated, do you consider alternate c...
Do you feel differently about using these in patients with a history of HR-negative breast cancer?
RIGHT Choice trial presented at SABCS 2022
Young healthy patient, ER/PR positive HER2 negative right breast cancer with a synchronous single site of oligometastatic disease in the right 4th rib...
What type of adjuvant chemotherapy would you offer? Would clinically positive lymph nodes or residual disease at the time of surgery change your decis...
Patient is pre-menopausal and has cT3cN1, grade 2, ER positive, Her 2 negative IDC. Metastatic disease to axillary LNs was biopsy-proven. Patient was ...
With the recent announcement that the phase 3 MonarchE trial met its primary endpoint.
Had mastectomy resulting in ypT1cN1a. Post menopausal female with good PS.
If so, under what circumstances?
Does your approach differ across the HER2 IHC spectrum?
MonarchE trial criteria includes "patients with four or more positive nodes, or one to three nodes and either tumor size ≥ 5 cm, histologic grade 3...
In the DAISY trial, ORR of 30.6% in T-DXd treated patients (n = 38) with HER2-null breast cancer
Fertility preservation already complete with embryo cryopreservation
Patient is young. Bilirubin normalizes when tucatinib is held, but again increases to grade 2 when it is restarted. Evaluation for hemolysis was negat...
Patient is a post-menopausal woman with 4 lymph node mets that was strongly ER+/PR+, HER2-negative invasive ductal carcinoma with a high Ki-67 w...
At initial diagnosis she had T1cN0 disease treated with lumpectomy and SLNB followed by 12 weeks of paclitaxel with 1 year of trastuzumab.
Would you consider definitive local therapy (surgery, radiation?) if she achieved a good response to initial systemic therapy?
Young patient, germline BRCA carrier with cT1cN0 to ypT2N0 disease after docetaxel/ cyclophosphamide x 4.
Which agents would you select and for how long would you treat them?
Patient is young and reoccurrence is one year after initial diagnosis of T1cN0 ER/PR positive, HER2-negative breast cancer treated with mastectomy, bu...
Patient underwent mastectomy for DCIS in the setting of previous lumpectomy and adjuvant radiation for the invasive breast cancer.
Patient has already received neo/adjuvant treatment with AC, paclitaxel, capecitabine, docetaxel, and carboplatin.
Would you consider neoadjuvant or adjuvant treatment and if so, which therapies? Patient initially had pT2N0 disease and recurrent disease is also ER+...
Patient previously received neoadjuvant ddAC-T with residual disease at surgery, followed by adjuvant capecitabine which was completed 2 months prior ...
High-risk criteria meaning >4 positive nodes and Ki67 >20%
This situation can feel uncomfortable. Would this feel safer if patient is s/p mastectomy and had TNBC?
Largest invasive focus is 0.4mm
CNS recurrence occurred within two years of prior neoadjuvant therapy
Is there any role for denosumab? How do you counsel patients regarding the benefit of bisphosphonates on breast cancer outcomes?
ER <1%; PR 45%, Her2 negative by IHC and FISH. Grade 3, Ki67: 80%.
Patient was on tamoxifen when progression occurred; unable to tolerate adjuvant AI.
How would this affect adjuvant radiation plan in breast conservation therapy patients and mastectomy patients?
Do you have a specific age cutoff?
Patient with T2N1 disease and isolated liver metastases. Axilla and liver completely responded to chemo + IO, but limited residual breast enhancement ...
We usually recommend copper IUDs, but that's not feasible in all women.
<40y/o female w/ initial biopsy showing G3 IDC with 80% ER+, 90% PR+, and HER2 positive (IHC 2+; 1.6 HER2/CEP17 ratio and 6.3 HER2 copies/nucleus.)...
Healthy 67 y/o woman, 1.5cm tumor, grade 3
Patient was given ddAC + T
Would you offer this patient chemotherapy? What are your thoughts about OFS plus AI and avoiding chemotherapy?
Would you choose to incorporate HER2-targeting agents, chemotherapy, endocrine therapy, or a mix of these?
Are there particular patient characteristics (e.g. age, ER%, Ki67, grade) that make you more likely to choose neoadjuvant endocrine therapy?
Would a pCR to neoadjuvant chemotherapy change your management? (ER <5%, PR <5%)
Do features such as nodal involvement, Ki-67, degree of ER positivity, etc. change your management? Would you use any gene expression assays to help y...
Would you prefer TCHP over TCH? Would you consider adding an anthracycline?
How would you approach additional systemic therapy? Would the clinical stage of the cancer affect your management?
Is adjuvant radiation and/or adjuvant chemotherapy indicated?
Would you consider an Oncotype or Mammaprint? Would your management change if the patient had 1-3 positive LNs on SLNBx (as opposed to ALND)?
Would you send Oncotype during chemotherapy if not sent already? Would you stop adjuvant chemotherapy if a prior Oncotype was 25 or less?
For patients with low risk, early stage, HR+/HER2- breast cancer who initiated endocrine therapy in order to delay their surgery due to the COVID 19 e...
What is your specific therapy choice and duration?
Would you send an Oncotype RS to determine the role of adjuvant chemotherapy and/or endocrine therapy?
Would you consider gene profiling to determine need for chemotherapy?
How would you balance the competing risks of these two diagnoses in her treatment?
Patient had a clinical T2N0 cancer at diagnosis, completed 6 cycles TCHP, and had 0.2mm residual disease with 80% cellularity, negative sentinel node.
How do clinical risk and Mammaprint/Oncotype scores affect your decision?
For example, will you recommend a certain vaccination timing in relationship to their treatment? Any concerns for reduced immune response or risks of ...
Given the data from KEYNOTE-522, would you try to incorporate chemotherapy in the treatment regimen?
Does tumor size impact your recommendation? High grade? Young patient age?
Does lymph node positivity change your management?
Would you consider ALND and /or XRT to axilla?
Patient case is triple positive inflammatory breast cancer
Of note, the patient received cytotoxic plus HER2 directed adjuvant therapy but declined endocrine therapy.
Pre-menopausal women make progesterone and their menses are typically lighter on tamoxifen because it's a mild endometrial ER stimulant blocking their...
Patient completed neoadjuvant therapy with TCH 2 years prior, and has no evidence of disease outside the CNS on PET/CT.
Would you test initial core biopsy (prior to neoadjuvant anastrozole) or surgical specimen? Any preference for Oncotype vs. Mammaprint?
Would your answer change if the new lesion is ALH/ADH?
She had had 4 prior biopsies. Would the fact that she received 2 months of neoadjuvant tamoxifen due to COVID change your approach?
Patient completed adjuvant AC-T 8 months prior to recurrence. BRCA negative, foundation medicine NGS pending.
PD-L1 is low and she has residual neuropathy from neoadjuvant paclitaxel.
Out of curiosity, I did tumor testing, and she does not have an activating ESR1 mutation.
Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?
If yes, would you offer tamoxifen or ovarian suppression plus AI?
This patient underwent mastectomy and ALND (10/28 positive lymph nodes). Immediately following axillary LN dissection (and prior to radiation) imaging...
Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal ...
Would you consider genomic assays before neoadjuvant chemotherapy? How would you modify your treatment given the COVID-19 pandemic?
What chemotherapy regimen would you recommend?
If so, after how many cycles of chemotherapy would you switch?
Does hormone receptor status impact your decision?
Would you forego anthracycline?
Is there a point at which there may be no benefit? More than 3 months from breast surgery? 6 months? 1 year?
If there is no response to neoadjuvant AC -->T, would you offer additional adjuvant chemotherapy?
Following the dosage guidelines based on absolute neutrophil count may cause the patient to end up receiving lower doses.
(For instance, TCX4 instead of AC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemotherap...
18471798818633171648265557818836363118676148011342518634171881717891951189373901700316914125991355015648158435166156804873148051427912332135581283112021128801261412078122761215211882933710509111031112111424109001109311029103181067537068660988510259103271053910276100219899961897375250963772397178703393699385935491189137925389819084904289977062891789467900796376088708873578938669858485708573843784328498841474328283794678087785525374735736704074857496745174077399730072062344712568646952700967825636557554824475354432452934240621711891
Papers discussed in this category
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-03-15
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10
Journal of the National Cancer Institute, 2010-07-07
J Natl Cancer Inst, 2006 Jul 5
J. Natl. Cancer Inst., 2010-07-07
J. Clin. Oncol., 2003-10-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
J. Clin. Oncol., 2019 Oct 16
Cancer, 2010-11-15
The breast journal, 2017-11
N. Engl. J. Med.,
The Lancet. Oncology, 2012-07
Annu. Rev. Med., 2015 Aug 28
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-06-20
Lancet,
Lancet Oncol, 2019 Feb 19
Lancet Oncol, 2019 Dec 02
Lancet Oncol, 2017 Oct 13
JNCI Cancer Spectr, 2021 May 28
Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15
JAMA oncology, 2017-07-01
Trials, 2013 Aug 19
Ann. Oncol., 2012 Jun 06
Cancer,
Annals of surgical oncology, 2014-10
N. Engl. J. Med.,
Ann Surg Oncol, 2022 Apr 04
The New England journal of medicine, 2019-06-20
The New England journal of medicine, 2018-07-12
PLoS ONE, 2018 May 16
The Lancet. Oncology, 2017-12
Breast, 2013 Dec 22
Breast, 2015 Oct 09
Lancet Oncol., 2020 Feb 14
The Lancet. Oncology, 2010-10
Breast Cancer Res. Treat.,
International journal of radiation oncology, biology, physics, 2005-07-15
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01
The New England journal of medicine, 2018-07-12
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-20
J. Clin. Oncol., 2019 Oct 16
Breast cancer research and treatment, 2014-11
The Lancet. Oncology, 2016-03
N Engl J Med, 2018 Oct 20
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01
The New England journal of medicine, 2019-02-14
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-20
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-12-01
JAMA Oncol, 2020 Aug 13
Journal of the National Cancer Institute, 2005-11-16
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10
N Engl J Med,
Cancer, 2020 Jun 10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-10
Journal of the National Cancer Institute, 1997-11-19
Journal of surgical oncology, 2017-06
The New England journal of medicine, 2016-08-25
Annals of oncology : official journal of the European Society for Medical Oncology, 2000-08
N Engl J Med, 2011 Oct 6
Lancet Oncol., 2012-01-01
N. Engl. J. Med., 2017-07-13
Lancet Oncol., 2018 Nov 06
Obstet Gynecol,
JAMA,
Cancer Prev Res (Phila), 2019 Aug 16
Lancet Oncol., 2014-11-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
N. Engl. J. Med., 2015-01-29
J Clin Oncol, 2019 Sep 18
Cancer, 2000-03-15
Front Oncol, 2020 Dec 03
Annals of surgical oncology, 2018-07
Clin Imaging, 2021 Feb 10
Clinical breast cancer, 2008-06
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-02-01
Breast Cancer Res, 2020 Nov 04
Breast Cancer Res Treat, 2011 Jul 27
Clin Breast Cancer, 2019 May 24
J Clin Oncol, 2020 Sep 16
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10
N Engl J Med, 2015 Jan 8
Cancer Manag Res, 2012 Jun 13
Ann Oncol, 2007 Feb 13
J Clin Oncol, 2021 Feb 04
JAMA, 2011-02-09
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-20
Clin Cancer Res,
Mol Cell Endocrinol, 2021 Jan 26
J. Clin. Oncol., 2020 Sep 20
Annals of Oncology, 2021 Sep 29
Cancer, 2019 Jul 18
J Clin Oncol, 2021 Dec 10
The Lancet. Oncology, 2014-02
Front Oncol, 2018 Apr 17
J Clin Oncol, 2022 Jan 18
The New England journal of medicine, 2011-06-23
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-05-10
Lancet, 2019 Dec 12
Lancet (London, England), 2016-02-27
N. Engl. J. Med., 2017 Jun 04
The New England journal of medicine, 2018-08-23
Breast Cancer Res Treat, 2016 Feb 18
Mol Cancer Ther, 2018 Mar 28
Eur J Cancer, 2014 Aug 12
N Engl J Med, 2021 Jun 03
N Engl J Med, 2022 Jun 05
Lancet (London, England), 2014-07-12
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-05-20
J Clin Oncol, 2022 Jan 07
Oncotarget,
Ann Surg,
Front Oncol, 2021 Apr 29
J Pathol Transl Med, 2019 Nov 06
J. Clin. Oncol., 2018-07-01
JACC CardioOncol, 2021 Mar 16
JACC. CardioOncology, 2020 Nov 17
Annals of surgery, 2010-09
Journal of reconstructive microsurgery, 2022 Feb 14
Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 2023 May 02
Breast Cancer Res Treat, 2009 Jun
Annals of surgical oncology, 2018-10
Lancet Oncol., 2015 Sep 09
The Journal of community and supportive oncology, 2014-10
Journal of the National Cancer Institute, 1996-10-16
The oncologist, 2019-03
Breast cancer research and treatment, 2019-04
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2020 Apr 22
Annals of oncology : official journal of the European Society for Medical Oncology, 2020 Sep 23
Annals of surgical oncology, 2020 Oct 30
JAMA oncology, 2021 Jan 01
Annals of oncology : official journal of the European Society for Medical Oncology, 2021 Oct 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 26
Journal of the National Comprehensive Cancer Network : JNCCN, 2020 Sep
Radiology, 2012 Dec 06
Annals of surgical oncology, 2019 Jun 21
Lancet Oncol, 2020 Apr 27
JAMA oncology, 2024 Jan 01
Clinical breast cancer, 2018 Apr 18
Breast cancer research and treatment, 2011 Jan 08